At Capital markets day, @novonordisk highlights the potential of unimolecular amylinR-GLP-1R co-agonism, revealing 13.1% placebo subtracted #weightloss in P 1 12 week data #obesity Some additional granularity on contributions to the primary composite endpoint in the Semaglutide FLOW trial #kidney disease #T2D via @novonordisk

GLP-1-based therapies are slowly approaching #bariatricsurgery level #weightloss and more exciting science to come. There is the impressive SURMOUNT-1 trial for tirzepatide #obesity nejm.org/doi/full/10.10… Among the compelling findings, 63% of subjects achieved > 20% #weightloss with 15 mg once weekly Tirzepatide over 72 weeks #obesity nejm.org/doi/full/10.10…

In 2021 the world celebrated the 100th anniversary of the discovery of #insulin surely one of the greatest medical breakthroughs of the 20th century #diabetes #T1D @NobelPrize @uoftmedicine academic.oup.com/edrv/article-a… #EndcrineReviews was pleased to publish a collection of articles devoted to advances #T1D #insulin #diabetes #islets A brief recap, here a comprehensive look at the human islet @powersac_TN @MouseCentral academic.oup.com/edrv/article-a…

For those of you who could not attend the #ENDO2020 sessions this am, due to scheduling or technical challenges, a summary thread #Diabetes #COVID19 We enter the #COVID19 era with an unprecedented set of pharmacological tools that can be used wisely to achieve personalized goals for #T2D

@AGA_Gastro highlights #NASH #NAFLD first up @VidalPuig Where do the fatty acids go? sciencedirect.com/science/articl… #NAFLD #NASH How much does the clock matter for pathophysiology or therapeutics #circadian sciencedirect.com/science/articl…